YOU ARE HERE:
Treatment interruptions news
page  of 3
 
Headline
Date
  BHIVA: Many patients and clinicians still need educating about the benefits of treatment
08.05.08
  Planned interruption of highly active antiretroviral therapy does not select drug resistance mutations in HIV-1-infected children
07.05.08
  Os benefícios de um início mais precoce do tratamento ARV superam o risco de toxicidades, revela o estudo SMART
28.04.08
  Benefit of starting HIV treatment early outweighs the risk of toxicities, SMART study shows
14.04.08
  SMART study reaffirms that HIV replication is harmful, even at CD4 counts above 350
14.04.08
  CROI: Biomarker changes may help explain detrimental effects of treatment interruption
07.02.08
  CROI: Risk of treatment interruption persists after restarting HAART
05.02.08
  High prevalence of asymptomatic heart disease in HIV-positive patients
09.01.08
  Up to 40% of ART recipients in Africa have died or discontinued treatment within two years
17.10.07
  ICAAC: In NNRTI-based regimens, stepwise discontinuation minimises risk of antiretroviral resistance
19.09.07
  IAS: ART interruption particularly unsafe for HIV-positive patients coinfected with hepatitis B or C
24.07.07
  Roche agrees to temporary suspension of nelfinavir's (Viracept) European license - updated
21.06.07
  Near-global nelfinavir (Viracept) recall 'very difficult situation'
20.06.07
  CROI: SMART substudy finds people on treatment less likely to transmit HIV, and may take fewer risks
04.03.07
  CROI: SMART analysis reveals slightly elevated risk of cardiovascular disease in people who interrupt therapy
27.02.07
  Studies finds risks in guided treatment interruptions even at higher CD4 cell threshold
01.02.07
  Asthma drug provides effective treatment for immune reconstitution inflammatory syndrome
31.01.07
  One-in-six interrupt treatment within two years of initiating ART
18.09.06
  SMART study - treatment breaks lower quality of life
28.08.06
  New data shed light on poor outcome in SMART study
17.08.06

page  of 3